ANERIS
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

ANERIS Trademark

Serial Number: 87265055

ANERIS is a trademark filed by ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED on December 12, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (253 trademarks)

CLONSHAUGH BUSINESS & TECHNOLOGY PARK
COOLOCK, DUBLIN 17 , IE

Entity Type: 77

Trademark Details

Filing Date

December 12, 2016

Registration Date

Not Registered

Published for Opposition

April 25, 2017

Goods & Services

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jul 27, 2020 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jul 27, 2020 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 20, 2019 EXRA
SOU EXTENSION 5 GRANTED
Dec 19, 2019 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 19, 2019 AITU
SOU EXTENSION 5 FILED
Dec 13, 2019 EXT5
SOU TEAS EXTENSION RECEIVED
Dec 13, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 19, 2019 EXRA
SOU EXTENSION 4 GRANTED
Mar 15, 2019 EX4G
SOU EXTENSION 4 FILED
Mar 15, 2019 EXT4
SOU TEAS EXTENSION RECEIVED
Mar 15, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 3, 2018 EXRA
SOU EXTENSION 3 GRANTED
Nov 1, 2018 EX3G
SOU EXTENSION 3 FILED
Nov 1, 2018 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 1, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 13, 2018 EXRA
SOU EXTENSION 2 GRANTED
Jun 11, 2018 EX2G
SOU EXTENSION 2 FILED
Jun 11, 2018 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 11, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 17, 2017 EXRA
SOU EXTENSION 1 GRANTED
Nov 15, 2017 EX1G
SOU EXTENSION 1 FILED
Nov 15, 2017 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 15, 2017 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 21, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 25, 2017 NPUB
PUBLISHED FOR OPPOSITION
Apr 25, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 5, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 13, 2017 CNSA
ASSIGNED TO EXAMINER
Mar 13, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 15, 2016 NWOS
NEW APPLICATION ENTERED
Dec 15, 2016 NWAP